Avantor, Inc. (NYSE: AVTR), a prominent global provider of essential products and services to clients in the life sciences and advanced technologies sectors, has announced the appointment of Corey Walker as President of Avantor’s Laboratory Solutions division. Walker will report directly to CEO Michael Stubblefield.
Stubblefield expressed confidence in Walker’s ability to lead the Laboratory Solutions business, citing his extensive knowledge of the industry, markets, and Avantor’s operations. He stated, “Corey’s deep knowledge of our end markets and industry, coupled with his familiarity with our organization and customers, makes him the ideal leader for our Laboratory Solutions business. We are very excited to welcome Corey back to Avantor to advance our business transformation and accelerate our growth strategy.”
Walker brings a wealth of experience and expertise in life sciences, advanced technologies, and applied materials to his new role. He previously served as Chief Executive Officer of ILC Dover, a global supplier to the biopharma and medical device markets. From 2016 to 2020, he held the position of Executive Vice President at Avantor, overseeing the Americas region as well as the global Biomaterials and Electronic Materials businesses. Walker holds a bachelor’s degree in marketing and business management from Brigham Young University and an MBA from Harvard Business School.
Commenting on his new role, Walker said, “Avantor has established an enviable market position, portfolio, and value proposition. I have always had great respect for Michael and the company, and I look forward to partnering with the team to enhance the customer experience, accelerate our transformation, and drive growth.”
Walker takes over from Randy Stone, who served as Executive Vice President of Laboratory Solutions. Stubblefield expressed gratitude for Stone’s contributions to Avantor, particularly in leading the Laboratory Solutions segment team and advancing the company’s business transformation.
Avantor’s new operating model, which includes two global operating segments – Laboratory Solutions and Bioscience Production – was implemented in January 2024. The company has reaffirmed its fiscal year 2024 guidance, as previously announced during its first quarter earnings call
